The story in the NY Times by Arlene Weintraub Potential for Deals was posted on a different thread (many thanks) but is worth borrowing.
This statement is interesting;
"One gateway for acquisitions in the biotech sector is research partnerships, and those are increasing as well."
And for additional emphasis;
"Robert J. Gould, the chief executive of Epizyme, said he was aware that research partnerships often blossomed into full-blown buyout offers."
The Phylogica model for broad therapeutic discovery alliances looks just about right.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
-0.025(1.89%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.32 | $1.30 | $478.1K | 365.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |